Experimental hepatitis b drug combo shows promise but study halted early

NCT ID NCT02738008

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. The study was terminated early, so results are limited, but it aimed to find a better way to control the virus long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

Research Site 1

Hong Kong, 999077, China
Research Site 2

Leipzig, 04103, Germany
Research Site 3

Busan, 602-739, South Korea
Research Site 4

Seoul, 110-744, South Korea
Research Site 5

Incheon, 405-760, South Korea
Research Site 6

Seoul, 120-752, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.